Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab.
Zimerman A, O'Donoghue ML, Ran X, Im K, Ott BR, Mach F, Zavitz K, Kurtz CE, Monsalvo ML, Wang B, Atar D, Keech A, Sabatine MS, Giugliano RP.
Zimerman A, et al. Among authors: wang b.
NEJM Evid. 2025 Jan;4(1):EVIDoa2400112. doi: 10.1056/EVIDoa2400112. Epub 2024 Dec 24.
NEJM Evid. 2025.
PMID: 39718423
Clinical Trial.